Previous Close | 93.17 |
1-Year Change | 56.04% |
6-Months Change | 21.73% |
3-Months Change | 3.2% |
Moving Avg (50d) | 90.664 |
Moving Avg (200d) | 82.58 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.51B |
Beta (3-Years) | 0.97 |
Revenue Growth (ttm) | 51.47% |
Net Profit Margin (ttm) | -91.87% |
Return On Assets (ttm) | -55.38% |
EPS (ttm) | -6.58 |
PE Ratio (ttm) | -14.16 |
Dividend Yield | % |
Asset Description: | Axsome Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-11-21 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
96.226 | 93.281 | 91.317 | 88.371 | 83.462 | 78.552 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |